

VIRTUAL FORMAT 14-15
October 2021
(WEST) Western European Summer Time

DIRECTOR

Luís Costa

Hospital de Santa Maria, Lisbon, Portugal

CO-DIRECTOR

Miguel Martín

Hospital General Universitario Gregorio Marañón, Madrid, Spain

# Innevation in Breast Cancer LISBON EDITION iBC 2021



## THURSDAY 14 October 2021

16:00 - 16:15	Opening remarks Luís Costa, Hospital de Santa Maria, Lisbon, Portugal
16:15 - 17:25	SESSION I PERSONALIZED SCREENING
Chairs:	AND PERSONALIZED PREVENTION  Fátima Vaz, Portuguese Institute of Oncology, Lisbon, Portugal  Teresa Ramón y Cajal, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
16:15 - 16:35	Breast cancer screening and prevention in women with germinal deleterious mutation Angela George, Royal Marsden Hospital, London, UK
16:35 - 16:55	Breast cancer screening and secondary prevention in women with past history of breast cancer Faina Nakhlis, Harvard Medical School, Boston, USA
16:55 - 17:25	Discussion
17:25 - 17:40	Break
17:40 - 19:10	SESSION II ADJUVANT THERAPY IN BREAST CANCER:
Chairs:	DEBATING AND EVOLVING  José Luís Passos Coelho, Hospital da Luz, Lisbon, Portugal Ángel Guerrero, Valencia Oncology Institute Foundation, Spain
17:40 - 18:00	Ki67 and genomic platforms Fernando Schmitt, University of Porto, Portugal
18:00 - 18:20	Genomics to support decision on adjuvant therapy Emilio Alba, Hospital Clínico Univ. Virgen de la Victoria, Málaga, Spain
18:20 - 18:40	Adjuvant post-neoadjuvant Edith A. Perez, Mayo Clinic, Florida, USA
18:40 - 19:10	Discussion

## FRIDAY 15 October 2021

16:00 - 17:00	SESSION III HER2 BREAST CANCER
Chairs:	Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain Luís Costa, Hospital de Santa Maria, Lisbon, Portugal
16:00 - 16:20	Brain metastases: what is new? Nancy U. Lin, Harvard Medical School, Boston, USA
16:20 - 16:40	Long-term responders to double blockade: what is next? Sandra Swain, Georgetown University School of Medicine, Washington, USA
16:40 - 17:00	Discussion
17:00 - 17:40	KEYNOTE LECTURE
17:00 - 17:30	Tumor microenvironment dynamics in breast cancer during neo-adjuvant chemotherapy Carlos Caldas, Cambridge Breast Cancer Research Unit, UK
17:30 - 17:40	Discussion
17:40 - 17:55	<b>Break</b>
17:55 - 19:05	SESSION IV LUMINAL A BREAST CANCER
Chair:	Evandro Azambuja, Institut Jules Bordet, Brussels, Belgium
17:55 - 18:15	Why do CDKis are effective in luminal A? Richard Finn, University of California, Los Angeles, USA
18:15 - 18:35	Endpoints during CDKis therapy: clinicians and patient's perspectives Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain
18:35 - 19:05	Discussion
19:05 - 19:20	Closing remarks Luís Costa, Hospital de Santa Maria, Lisbon, Portugal



#### Organized by



COCLOFOTUN
MEDICAL MARKETING SPECIALISTS

Tel.: (+351) 912 950 061
e-mail: ibc-lisbon@doctaforum.com
www.innovationinbreastcancer.com/lisbon



### **Under the auspices of**





